BVS vs SOLV: fair value comparison
Bioventus Inc. and Solventum Corporation · Updated 2026-09-07
BVS currently screens as fairly valued while SOLV screens as overvalued. Within Healthcare, BVS currently sits closer to the top of our discount ranking. BVS carries the stronger quality grade.
| BVS | SOLV | |
|---|---|---|
| Verdict | Fairly valued | Overvalued |
| Last price | $13.47 | $91.69 |
| 12-month range | $6.56–$13.47 | $64.35–$90.95 |
| Sector rank | #85 of 113 Healthcare | #87 of 113 Healthcare |
| Quality grade | D | F |
| Leverage | Moderate | High |
| Margin trend | — | Contracting |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BVS fair value analysis · SOLV fair value analysis